Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
123I-MNI-388 is a radiopharmaceutical, likely intended for diagnostic imaging. The "123I" prefix indicates that it contains Iodine-123, a radioactive isotope commonly used in nuclear medicine for imaging. The "MNI-388" component refers to a specific ligand that is labeled with Iodine-123. While the precise chemical structure and biological target of the MNI-388 ligand are not publicly available, compounds with the "MNI" prefix are often developed as radioligands for imaging specific biological receptors or transporters in research and clinical settings. As a radiopharmaceutical, its mechanism involves the selective binding of the MNI-388 ligand to its target, allowing the Iodine-123 radioisotope to be localized and detected by imaging techniques such as SPECT (Single-Photon Emission Computed Tomography), thereby providing diagnostic information about the distribution and function of the target in the body.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 123I-MNI-388.